Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples | Zendy

Onya Opota | Zendy; René Brouillet | Zendy; Gilbert Greub | Zendy; Katia Jaton | Zendy

Open Access

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples

Author(s) -

Onya Opota,

René Brouillet,

Gilbert Greub,

Katia Jaton

Publication year - 2020

Publication title -

pathogens and disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.983

H-Index - 105

ISSN - 2049-632X

DOI - 10.1093/femspd/ftaa061

Subject(s) - sputum , covid-19 , medicine , bronchoalveolar lavage , viral load , virology , real time polymerase chain reaction , diagnostic test , respiratory tract , pathology , respiratory system , virus , biology , lung , veterinary medicine , tuberculosis , disease , infectious disease (medical specialty) , biochemistry , gene

Objectives:In order to cope with the rapid spread of the COVID-19 pandemic, we introduced on our in-house high-throughput molecular diagnostic platform (MDx Platform) a real-time reverse transcriptase PCR (RT-PCR) to detect the SARS-CoV-2 from any clinical specimens. The aim of this study was to compare the RT-PCR results obtain with the MDx Platform and the commercial assay cobas SARS-CoV-2 (Roche) on nasopharyngeal swab and other clinical specimens including sputum, bronchial aspirate, bronchoalveolar lavage and anal swabs. Methods: Samples received in our laboratory from patients suspected of COVID-19 (n = 262) were tested in parallel with our MDx platform SARS-CoV-2 PCR and with the cobas SARS-CoV-2 test. Results: The overall agreement between the two tests for all samples tested was 99.24% (260/262), which corresponded to agreements of 100% (178/178) on nasopharyngeal swabs, 95.45% (42/44) on lower respiratory tract specimen with discordant resultS obtained for very high cycle threshold (Ct) value and 100% (40/40) on anorectal swabs. The Ct values for nasopharyngeal swabs displayed an excellent correlation (R2 > 96%) between both tests. Conclusions: The high agreements between the cobas SARS-CoV-2 test and the MDx platform supports the use of both methods for the diagnostic of COVID-19 on various clinical samples. Very few discrepant results may occur at very low viral load.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research